Transition from Basal Bolus to Once-Weekly Subcutaneous Semaglutide and Basal Insulin in Patients with Type 2 Diabetes Mellitus (TRANSITION-T2D)-A Prospective Randomized Controlled Trial

被引：0
|
作者：
Rodriguez, Paloma
Breslaw, Nikki
Bena, James F.
Xiao, Huijun
Jenkins, Kimberly
Isaacs, Diana
Zhou, Keren
Griebeler, Marcio L.
Burguera, Barto
Pantalone, Kevin M.
机构：
来源：
DIABETES | 2023年 / 72卷
关键词：
D O I：
10.2337/db23-74-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
74-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [1] An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes
    Ildiko Lingvay
    Andrei-Mircea Catarig
    Jack Lawson
    Barrie Chubb
    Anders Gorst-Rasmussen
    Lyndon Marc Evans
    Diabetes Therapy, 2023, 14 : 123 - 137
  • [2] De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D)
    Rodriguez, Paloma
    Breslaw, Nikki
    Xiao, Huijun
    Bena, Jim
    Jenkins, Kimberly
    Isaacs, Diana
    Zhou, Keren
    Griebeler, Marcio L.
    Burguera, Bartolome
    Pantalone, Kevin M.
    DIABETES OBESITY & METABOLISM, 2024,
  • [3] An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal-Bolus Insulin in Type 2 Diabetes
    Lingvay, Ildiko
    Catarig, Andrei-Mircea
    Lawson, Jack
    Chubb, Barrie
    Gorst-Rasmussen, Anders
    Evans, Lyndon Marc
    DIABETES THERAPY, 2023, 14 (01) : 123 - 137
  • [4] Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
    Rodbard, Helena W.
    Lingvay, Ildiko
    Reed, John
    de la Rosa, Raymond
    Rose, Ludger
    Sugimoto, Danny
    Araki, Eiichi
    Chu, Pei-Ling
    Wijayasinghe, Nelun
    Norwood, Paul
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (06): : 2291 - 2301
  • [5] Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
    Bajaj, Harpreet S.
    Bergenstal, Richard M.
    Christoffersen, Andreas
    Davies, Melanie J.
    Gowda, Amoolya
    Isendahl, Joakim
    Lingvay, Ildiko
    Senior, Peter A.
    Silver, Robert J.
    Trevisan, Roberto
    Rosenstock, Julio
    DIABETES CARE, 2021, 44 (07) : 1586 - 1594
  • [6] Evaluating Patient and Provider Preferences for a Once-Weekly Basal Insulin in Adults with Type 2 Diabetes
    Kerr, David
    Rajpura, Jigar Ramesh
    Namvar, Tarlan
    PATIENT PREFERENCE AND ADHERENCE, 2024, 18 : 411 - 424
  • [7] Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
    Buse, John B.
    Christensen, Helene Nordahl
    Harty, Brian J.
    Mitchell, Julie
    Soule, Benjamin P.
    Zacherle, Emily
    Cziraky, Mark
    Willey, Vincent J.
    BMJ OPEN DIABETES RESEARCH & CARE, 2023, 11 (03)
  • [8] Efficacy and safety of once-weekly basal insulin versus once-daily basal insulin in patients with type 2 diabetes: A systematic review and meta-analysis
    Wang, Xinxin
    Xiao, Wei
    Liang, Zhanpeng
    Li, Shixiang
    Tang, Qizhi
    MEDICINE, 2023, 102 (52) : E36308
  • [9] Efficacy and safety of switching to insulin icodec, a once-weekly basal insulin, vs insulin glargine U100 in patients with type 2 diabetes inadequately controlled on OADs and basal insulin
    Bajaj, H.
    Isendahl, J.
    Gowda, A.
    Stachlewska, K.
    Rosenstock, J.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S317 - S317
  • [10] Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial
    Bue-Valleskey, Juliana M.
    Kazda, Christof M.
    Ma, Chenchen
    Chien, Jenny
    Zhang, Qianyi
    Chigutsa, Emmanuel
    Landschulz, William
    Haupt, Axel
    Frias, Juan P.
    DIABETES CARE, 2023, 46 (05) : 1060 - 1067
12345